ProRhythm believes that the development of its HIFU system for the treatment of Atrial Fibrillation has the potential to transform AF ablation by providing a fast, safe and successful treatment to Atrial Fibrillation. Through our clinical trials, we believe that we will demonstrate that we have the state of the art treatment for AF.

Successful results could have the power to transform the way in which the medical community treats this extraordinary patient population.

It is estimated that there are 8.2 million patients in world with AF, 2.5 million of which are in the United States. In the vast majority of cases, these patients are being treated with palliative drug therapy. ProRhythm is committed to providing a curative solution for these patients.